Long-term continuous exposure to static magnetic field reduces popolysaccharide-induced cytotoxicity of fibroblasts

International Journal of Radiation Biology

Volumn 84, Issue 3, 2008, Pages 219-226

  Lin, Che Tong ^a   Lee, Sheng Yang ^a   Chen, Chun Yang ^a   Chen, Chi An ^a   Lin, Chih Ping ^a   Huang, Haw Ming ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Anti inflammatory effects; Antioxidants; Bacteria; E M fields; Immunology

Indexed keywords

ANTIOXIDANT; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CELL STRAIN 3T3; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; FIBROBLAST; IMMUNE RESPONSE; INFLAMMATION; MAGNETIC FIELD; NONHUMAN; PRIORITY JOURNAL; STATIC MAGNETIC FIELD;

ANIMALS; CELL SURVIVAL; CYTOKINES; ELECTROMAGNETIC FIELDS; FIBROBLASTS; LIPOPOLYSACCHARIDES; MAGNETICS; MICE; NIH 3T3 CELLS;

EID: 40049089737     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.1080/09553000801902158     Document Type: Article

References (42)

1. Aderka D, Le J, Vilcek J. 1989. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. The Journal of Immunology 143:3517-3523.
2. Agarwal S, Piesco NP, Riccelli AE. 1995. Differential expression of IL-1β, TNF-α, IL-6, and IL-8 in human monocytes in response to lipopolysaccharides from different microbes. Journal of Dental Research 74:1057-1065.
3. Aldinucci C, Garcia JB, Oalmi M, Sgaragli G, Benocci A, Meini A, Pessina F, Rossi C, Bonechi C, Pessina GP. 2003. The effect of strong static magnetic field on lymphocytes. Bioelectromagnetics 24:109-117.
4. Aoki H, Yamazaki H, Yoshino T, Akagi T. 1990. Effects of static magnetic fields on membrane permeability of a cultured cell line. Research Communications in Chemical Pathology and Pharmacology 69:103-106.
5. Ashdown H, Poole S, Boksa P, Luheshi GN. 2007. Interleukin-1 receptor antagonist as a modulator of gender differences in the febrile response to lipopolysaccharide in rats. The American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 292:R1667-1674.
6. Barton BE, Jackson JV. 1993. Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model. Infection and Immunity 61:1496-1499.
7. Bernstein JM, Hasse E, Scannapieco F, Dryja D, Wolf J, Briles D, King J, Wilding GE. 2006. Bacterial interference of penicillinsensitive and -resistant Streptococcus pneumoniae by Streptococcus oralis in an adenoid organ culture: Implications for the treatment of recurrent upper respiratory tract infections in children and adults. Annals of Otology, Rhinology and Laryngology 115:350-356.
8. Coots A, Shi R, Rosen AD. 2004. Effect of a 0.5-T static magnetic field on conduction in guinea pig spinal cord. Journal of The Neurological Sciences 222:55-57.
9. Darendeliler MA, Sinclair PM, Kusy RP. 1995. The effects of samarium-cobalt magnets and pulsed slectromagnetic fields on tooth movement. American Journal of Orthodontics and Dentofacial Orthopedics 107:578-588.
10. Dinarello CA. 1998. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. International Reviews of Immunology 16:457-499.
11. Dziarski R, Tapping PI, Tobias PS. 1998. Binding of bacterial peptidoglycan to CD14. Journal of Biological Chemistry 273:8680-8690.
12. Eccles NK. 2005. A critical review of randomized controlled trials of static magnets for pain relief. The Journal of Alternative and Complementary Medicine 11:495-509.
13. Feinendegen LE, Muhlensiepen H. 1987. In vivo enzyme control through a strong stationary magnetic field - the case of thymidine kinase in mouse bone marrow cells. International Journal of Radiation Biology 52:469-479.
14. Fiers W. 1991. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Letter 285:99-212.
15. Greisman SE, Yong EJ, Woodward WE. 1996. Mechanisms of endotoxin tolerance. IV. Specificity of the pyrogenic refractory state during continuous intravenous infusions of endotoxin. The Journal of Experimental Medicine 124:983-1000.
16. Hermann C, Spreitzer I, Schröder NWJ, Morath S, Lehner MD, Fischer W, Schütt C, Schumann RR, Hartung T. 2002. Cytokine induction by purified lipoteichoic acids from various bacterial species - role of LBP, sCD14, CD14 and failure to induce IL-12 and subsequent IFN-γ release. European Journal of Immunology 32:541-551.
17. Jiang Q, Akashi S, Miyake K. 2000. Lipopolysaccharide induces physical proximity between CD14 and Toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B. The Journal of Immunology 165:2163-2167.
18. Mathiak G, Kabir K, Grass G, Keller H, Steinringer E, Minor T, Rangger C, Neville LF. 2003. Lipopolysaccharides from different bacterial sources elicit disparate cytokine responses in whole blood assays. International Journal of Molecular Medicine 11:41-44.
19. Matthys P, Mitera T, Heremans H, Van Damme J, Billiau A. 1995. Anti-gamma interferon and anti-interleukin-6 antibodies affect staphylococcal enterotoxin B induced weight loss, hypoglycemia, and cytokine release in D-galactosamine-sensitized and unsensitized mice. Infection and Immunity 63:1158-1164.
20. Mizuhara H, O'Neill E, Seki N, Ogawa T, Kusunoki C, Otsuka K, Satoh S, Niwa M, Senoh H, Fujiwara H. 1994. T cell activation-associated hepatic injury: Mediation by tumor necrosis factors and protection by interleukin 6. The Journal of Experimental Medicine 179:1529-1537.
21. Mullender M, El Haj AJ, Yang Y, van Duin MA, Burger EH, Klein-Nulend J. 2004. Mechanotranduction of bone cells in vitro: Mechanobiology of bone tissue. Medical and Biological Engineering and Computing 43:14-21.
22. Natanson C, Esposito CJ, Banks SM. 1998. The sirens' songs of confirmatory sepsis trials: Selection bias and sampling error. Critical Care Medicine 26:1927-1931.
23. Pacini S, Vannelli GB, Barni T, Ruggiero M, Sardi I, Pacini P, Gulisano M. 1999. Effects of 0.2 T static magnetic field on human neurons: Remodeling and inhibition of signal transduction without genome instability. Neuroscience Letters 267:185-188.
24. Page RC. 1991. The role of inflammatory mediator in the pathogenesis of periodontal disease. Journal of Periodontal Research 26:230-242.
25. Piguet PF, Vesin C, Grau GE, Thompson RC. 1993. Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 5:57-61.
26. Portnoy J, Pan T, Dinarello CA, Shannon JM, Westcott JY, Zhang L, Mason RJ. 2006. Alveolar type II cells inhibit fibroblast proliferation: Role of IL-1alpha. The American Journal of Physiology - Lung Cellular and Molecular Physiology 290:L307-316.
27. Riley MA, Walmsley AD, Harris IR. 2001. Magnets in prosthetic dentistry. Journal of Prosthetic Dentistry 86:137-142.
28. Rodel F, Keilholz L, Herrmann M, Sauer R, Hildebrandt G. 2007. Radiobiological mechanisms in inflammatory diseases of low-dose radiation therapy. International Journal of Radiation Biology 6:357-366.
29. Sakurai H, Okuno K, Kubo A, Nakamura K, Shoda M. 1999. Effect of a 7-tesla homogeneous magnetic field on mammalian cells. Bioelectrochemistry and Bioenergetics 49:57-63.
30. Salerno S, Lo Casto A, Caccamo N, d'Anna C, de Maria M, Lagalla R, Scola L, Cardinale AE. 1999. Static magnetic fields generated by a 0.5 T MRI unit affects in vitro expression of activation markers and interleukin release in human peripheral blood mononuclear cells (PBMC). International Journal of Radiation Biology 75:457-463.
31. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. 1990. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 75:40-47.
32. Steensberg A, Fischer CP, Keller C, Møller K, Pedersen BK. 2003. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. The American Journal of Physiology Endocrinology and Metabolism 285:E433-437.
33. Suda T, Ueno S. 1994. Magnetic orientation of red blood cell membranes. IEEE Transactions on Magnetics 20:4713-4715.
34. Tilg H, Dinarello CA, Mier JW. 1997. IL-6 and APPs: Antiinflammatory and immunosuppressive mediators. Immunology Today 18:428-432.
35. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. 1994. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83:113-118.
36. Ulich TR, Yin S, Guo K, Yi ES, Remick D, del Castillo J. 1991. Intratracheal injection of endotoxin and cytokines. II. Interleukin-6 and transforming growth factor beta inhibit acute inflammation. American Journal of Pathology 38:1097-1101.
37. Wang JE, Dahle MK, McDononald M, Fosrer SJ, Aasen AO, Thiemermann C. 2003. Peptidoglycan and lipoteichoic acid in Gram-positive bacterial sepsis: Receptors, signal transduction, biological effects, and synergism. Sock 20:402-414.
38. Wang JHC, Thampatty BP. 2006. An introductory review of cell mechanobilogy. Biomechanics and Modeling in Mechanobiology 5:1-16.
39. Wang N, Butler JP, Ingber DE. 1993. Mechanotransduction across the cell surface and through the cytoskeleton. Science 260:1124-1127.
40. Weinberger A, Nyska A, Giler S. 1996. Treatment of experimental inflammatory stnovitis with continuous magnetic field. Israel Journal of Medical Sciences 32:1197-1201.
41. West MA, Heagy W. 2002. Endotoxin tolerance: A review. Critical Care Medicine 30:64-73.
42. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, Achong MK. 1998. IL-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory responses. The Journal of Clinical Investigation 101:311-320.